Pfizer Calls Early End to Celebrex Safety Study in Children

Pfizer terminated a long-term safety study of its blockbuster painkiller Celebrex in juvenile arthritis patients, citing difficulties in recruiting patients and a low rate of adverse events.
Fox Business